androgen deprivation therapy
ApprovedSmall molecule
Johnson & Johnsonandrogen deprivation therapy is one of 174 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.
8
Indications
71
Total Trials
45
Active Trials
173
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1399 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1androgen deprivation therapy
Johnson & JohnsonApproved
Novantrone
PfizerPreclinical
Mekinist
NovartisPreclinical
Trexall
Alnylam PharmaceuticalsPreclinical
Duragesic
CCephalon
Preclinical
Viagra
VViatris Specialty LLC
Preclinical
Ranexa
MMenarini International Operations Luxembourg SA
Preclinical
Triptorelin Pamoate
IpsenPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer50 trials
Show 47 more trials
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
Completed·—·Phase 2·NCT00776594·102 enrolled
PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer
Recruiting·AAffidea Nu-med Center of Oncological DIagnostics and Therapy·Phase 2/3·NCT07426055·1,200 enrolled
Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients
Active, not recruiting·SSir Mortimer B. Davis - Jewish General Hospital·Phase 3·NCT02303327·307 enrolled
Radiation and Androgen Ablation for Prostate Cancer
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT01517451·45 enrolled
PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer
Recruiting·AAffidea Nu-med Center of Oncological DIagnostics and Therapy·Phase 2/3·NCT07426094·1,600 enrolled
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT06305832·102 enrolled
Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer
Active, not recruiting·WWashington University School of Medicine·Preclinical·NCT05628363·28 enrolled
Metastatic Prostate Cancer3 trials
Prostate Carcinoma2 trials
Prostatectomy1 trial
14 more indications
Androgen Deprivation Therapy1 trial
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT03543189·44 enrolled
Abiraterone Acetate1 trial
Nivolumab1 trial
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
Active, not recruiting·—·Phase 2·NCT04126070·60 enrolled
Exercise1 trial
EXTEND Exercise Trial
Completed·—·Phase 2·NCT02256111·26 enrolled
Metastases1 trial
Radiation Therapy1 trial
First Line Therapy1 trial
Recurrence1 trial
Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)
Not yet recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT05778097·103 enrolled
Cardiovascular Disease1 trial
Prostatic Neoplasms1 trial
Androgen Axis Suppression1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company